Please wait while we load the requested 10-K report or click the link below:
March 10, 2016
Pulmatrix Reports 2015 Financial Results; Provides 2016 Outlook on Pulmonary Disease Pipeline
2015 was a transformational year lead assets for COPD and cystic fibrosis continue to progress in clinical development.
LEXINGTON, MA Pulmatrix, Inc. (NASDAQ: PULM) today announces 2015 financial results, reviews the Companys recent progress, and provides an outlook for 2016 for its pulmonary disease development pipeline.
2015 was a transformational year for Pulmatrix. We positioned the Company to have two iSPERSE-based product candidates in clinical trials during 2016, strengthened our balance sheet, and became publicly listed on NASDAQ, said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. We expect clinical data in the first half of 2016 on PUR0200 targeting the large market of COPD, and the second program, PUR1900, will enter the clinic this year targeting fungal infections in cystic fibrosis patients. As our product pipeline and iSPERSE technology continue to advance, we feel the Company is well positioned for clinical success in 2016 and beyond.
In a March 10th letter to shareholders, Dr. Clarke added that the Company aims to keep up its aggressive pace in 2016 thanks to the dedication of our scientists and management to developing products that can make a real difference in the lives of patients, and to the much-appreciated support of our shareholders.
Planned 2016 Milestones
Pulmatrix has two major priorities for 2016: Pulmatrix intends to continue to advance PUR0200, a branded generic bronchodilator for COPD, through clinical development and intends to initiate clinical testing for PUR1900, an inhaled anti-fungal initially targeted for patients with cystic fibrosis.
|||Report data from European pilot pharmacokinetic bioequivalence clinical study of PUR0200, funded as part of a previously disclosed research collaboration agreement, in the first half of 2016|
|||Initiate development work in the second half of 2016 to support a future European pivotal pharmacokinetic bioequivalence approval study|
|||Expand current research collaboration focused on US development to form a more expansive development and commercialization partnership in the second half of 2016|
|||Initiate Phase 1/1b trial in fungal infections in cystic fibrosis patients in the second half of 2016|
|||Expand PUR1900 program to indication(s) outside of cystic fibrosis|
|||Identify the active pharmaceutical ingredient for an IPF candidate(s), which could include a small molecule kinase inhibitor and/or a biologic in the first half of 2016|
The following information was filed by Pulmatrix, Inc. (PULM) on Thursday, March 10, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Pulmatrix, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Pulmatrix, Inc..